The FDA approved Jakafi (ruxolitinib) in 2019 as a treatment for graft-versus-host disease (GVHD) that doesn’t respond to steroids. The addition of the oral Janus kinase 1/2 inhibitor to the GVHD armamentarium has been a major advance, but some patients don’t respond to Jakafi. Moreover, in a review paper published in the American Journal of Hematology, lead and corresponding author Portia Smallbone, M.B.B.S., of the University of Texas MD Anderson Cancer Center, and her MD Anderson colleagues, Rohtesh S. Mehta, M.P.H., M.S., and Amin Alousi, M.D., say the benefits of Jakafi have not translated into improved overall survival. There is, they wrote, “a clear and urgent need for better therapies in patients suffering from SR-AGVHD [steroid-refractory graft-versus-host-disease].” In the la

See Full Page